Greehey CCRI Fall Seminar Series: Poulikos I. Poulikakos, PhD, Mount Sinai (virtual)
Event Date & TimeOctober 14, 2022 at 12 noon CT
LocationZOOM Link below
"Next-Generation Strategies Targeting Oncogenic Signaling for Cancer Therapy"
Greehey CCRI Host: Angelina Vaseva, PhD
Zoom Meeting: zoom.us/j/91409021393?pwd=YzloQnFvalFtVXE4T0YybWMxZEZsQT09
Meeting ID: 914 0902 1393
Save to CalendarAdd to Calendar
About the Speaker(s)
Dr. Poulikakos is an Associate Professor in the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai in New York. He received his Ph.D. in Biology in 2002 from the School of Biology, University of Athens, Greece, and he subsequently pursued postdoctoral training on cancer biology and signaling, first in Dr. Joseph Testa’s laboratory at the Fox Chase Cancer Center in Philadelphia and subsequently in Dr. Neal Rosen’s laboratory, at Memorial Sloan Kettering Cancer Center (2006-2012) in New York, before joining Mount Sinai in 2012.
Dr. Poulikakos' research is focused on investigating mechanisms of growth factor signaling regulation and of tumor response to pharmacologic targeting of its components using small molecule inhibitors. During his postdoctoral work, and subsequently, as an independent investigator, he has linked biochemical mechanisms of action of BRAF and MEK inhibitors to their structural properties and characterized mechanisms of adaptive and acquired tumor resistance to these drugs: PMID: 20179705, PMID: 22113612, PMID: 23153539, PMID: 23667175, PMID: 26343582, PMID: 27523909, PMID: 28984291, PMID: 33568355. More recently, his group characterized different RAS-mutants for their dependence on RTK/SHP2 signaling and identified biomarkers of tumor response to SHP2-based drug combinations for the treatment of RAS-mutant and BRAF-mutant cancers (PMID: 30605687). Finally, his group has recently elucidated molecular mechanisms determining tumor response to CDK4/6 inhibitors and developed next-generation pharmacologic strategies (PROTACs) to effectively target CDK4/6 signaling for cancer therapy (PMID: 34568836).
He has received a number of fellowships and awards, including the Sidney Kimmel Award for Cancer Research, The Society of Melanoma Research Young Investigator Award, as well as awards from the Melanoma Research Alliance, the Melanoma Research Foundation, The Dermatology Foundation, and the Harry J. Lloyd Charitable Trust, among others.